The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The End of the Beginning: COVID-19 Vaccines & Other Conundrums

The End of the Beginning: COVID-19 Vaccines & Other Conundrums

December 9, 2020 • By Philip Seo, MD, MHS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Phil Seo, MD, MHS

“It’s like winning Powerball.”

You Might Also Like
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines
  • COVID-19 Immunization Day: It Won’t Be Long Before We Can Hug Again
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
Also By This Author
  • Thinking Big, Thinking Small

For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After some fits and starts, I finally struck upon a pat answer that I liked: “It’s a little bit like asking me how you should spend the money you’re going to win by playing Powerball. There are more than 200 vaccines under development. Let’s just see what happens.”

Looks like that answer won’t cut it anymore.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

On Nov. 16, Moderna announced the results of its COVE study, and the world, collectively, breathed a sigh of relief.

The COVE study examined the efficacy of the Moderna vaccine candidate at preventing COVID-19.1 More than 30,000 participants were enrolled, 95 of whom were subsequently diagnosed with COVID-19. All but five of those patients had received a placebo, indicating the vaccine was 94.5% effective at preventing patients from developing COVID-19. The most common, medically significant (i.e., Grade 3) adverse events were fatigue, myalgias and arthralgias, which are not all that surprising for a vaccine study.

On Nov. 18, Pfizer and BioNTech announced the results of the phase 3 study of their COVID-19 vaccine candidate.2 Of the 43,661 participants, 170 patients were eventually diagnosed with COVID-19. Only eight of those patients had received the vaccine, meaning it was 95% effective at preventing the disease. The most common medically significant adverse events were fatigue and headache, which again, seem like a small price to pay for immunity against SARS CoV-2.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

On Nov. 23, AstraZeneca also came through with good news, sort of. Unlike the Moderna and Pfizer vaccines, which use mRNA to trigger an immune response, the AstraZeneca vaccine uses a modified adenovirus to deliver the goods.

When administered to 8,895 volunteers, the AstraZeneca vaccine was 62% effective at preventing COVID-19.3

That’s above the 50% efficacy threshold announced by FDA Commissioner Stephen Hahn as the minimum a vaccine would need to achieve to win FDA approval.4 And it is certainly better than 0%, which is the amount of protection that most of us currently have against COVID-19.

Fortunately, AstraZeneca made a mistake. The first 2,741 patients enrolled in the study received a lower dose of the vaccine than originally planned.5 Because the error was not felt to impact the vaccine’s safety, the study was allowed to continue. That was a truly brilliant decision, because it turns out that the lower dose of the vaccine was 90% effective at preventing COVID-19, which brings it in the ballpark of the other two vaccines.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Rheuminations Tagged With: COVID-19

You Might Also Like:
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines
  • COVID-19 Immunization Day: It Won’t Be Long Before We Can Hug Again
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • Early Lessons from the COVID-19 Pandemic: A Q&A with Chris Phillips, MD

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.